ANXA2 and breast carcinoma: ANXA2 has been reported as an independent predictor of poor prognosis in breast cancer patients receiving neoadjuvant therapy, [81] however overexpression of ANXA2 alone did not have a statistically significant impact on DRFS among GSE25066 patients.